Tegafur Injection
Function and Efficacy
This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of the anti-pyrimidine class. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No severe bone marrow suppression was observed in the chronic toxicity test, and the effect on immunity was relatively mild.
Ingredients
The chemical name of this product is: 1-(tetrahydro-2-furanyl)-5-fluoro-2,4(1H,3H)-pyrimidinedione. Its structural formula is: Molecular formula: C8H9FN2O3 Molecular weight: 200.17
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| TegafurIngredients |
This product is a derivative of fluorouracil. It is activated by the liver in the body and gradually converted into fluorouracil to play an anti-tumor role. It can interfere with and block the synthesis of DNA, RNA and protein, and mainly acts on the S phase. It is a cell cycle-specific drug of the anti-pyrimidine class. Its mechanism of action, efficacy and anti-tumor spectrum are similar to those of fluorouracil, but it has a long-lasting effect, good absorption and low toxicity. The chemotherapy index is twice that of fluorouracil, and the toxicity is only 1/4 to 1/7 of that of fluorouracil. No severe bone marrow suppression was observed in the chronic toxicity test, and the effect on immunity was relatively mild. More |
17902-23-7 | 10 |
Appearance
This product is an almost colorless clear liquid.
Indication
It is mainly used to treat digestive tract tumors, such as gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, and can also be used for breast cancer.
Usage and Dosage
The daily dose for adults is 800-1000 mg or 15-20 mg/kg per day based on body weight. It is dissolved in 500 ml of 5% glucose injection or 0.9% sodium chloride injection and administered by intravenous drip once a day. The total amount is 20-40 g per course of treatment.
Adverse Reactions
Bone marrow suppression reaction is mild, with a decrease in white blood cells and platelets. Neurotoxic reactions include headache, dizziness, ataxia, mental state changes, etc. A few patients experience nausea, vomiting, diarrhea, and changes in liver and kidney function. Local injection sites have phlebitis, swelling, and pain. Fever, skin itching, and pigmentation are occasionally seen.
Precautions
It is forbidden to use in pregnant and lactating women.
Special Population Medication
Precautions for children: No experimental data or reliable literature. Precautions for pregnancy and lactation: Do not use. Precautions for the elderly: No experimental data or reliable literature.
Drug Interactions
Tegafur is alkaline and contains carbonate. Avoid using it with drugs containing calcium or magnesium ions or with strong acidity.
Storage
Keep in a light-proof and airtight container.
Packaging Specification
10ml:0.5g
Validity Period
24 months
Manufacturer
Harbin Pharmaceutical Group Bioengineering Co., Ltd.
-
Founded in:
1995-02-20 -
Address:
No. 99, Zhuhai Road, Limin Development Zone, Hulan District, Harbin -
Tax NO.:
91230111128024298B -
Registered Funds:
186.0655 million yuan -
Website:
-
Email: